Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Collegium Pharmaceutical, Inc. - Common Stock (NQ:COLL)

35.23 +0.36 (+1.03%)
Streaming Delayed Price Updated: 12:00 PM EDT, May 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Collegium Pharmaceutical, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Collegium Pharmaceutical’s Q1 Earnings Call: Our Top 5 Analyst Questions
Collegium Pharmaceutical’s first quarter was marked by solid execution and positive market reaction, supported by robust growth in its ADHD and pain manageme... 
Via StockStory
Topics Earnings
News headline image
Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with servi... 
Via StockStory
Topics Economy
News headline image
1 Healthcare Stock with Competitive Advantages and 2 We Brush Off
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory de... 
Via StockStory
News headline image
COLL Q1 Deep Dive: ADHD Portfolio Expansion and Pain Segment Stability Drive Results
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) announced better-than-expected revenue in Q1 CY2026, with sales up 8.9% year on year to $193.5 ... 
Via StockStory
Collegium Pharmaceutical (NASDAQ:COLL) Surges on Q1 Earnings Beat as JORNAY PM Revenue Jumps 36% ↗
Via Chartmill
Topics Earnings
Collegium Pharmaceutical Inc (NASDAQ:COLL) Priced for a Value Rebound ↗
Via Chartmill
News headline image
Collegium (COLL) Q1 2026 Earnings Transcript ↗
Collegium (COLL) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q1 CY2026 Expectations, Stock Soars
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 8.9% year o... 
Via StockStory
News headline image
Collegium Pharmaceutical (COLL) Q1 Earnings Report Preview: What To Look For
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be announcing earnings results this Thursday before market open. Here’s what investors sho... 
Via StockStory
News headline image
1 Small-Cap Stock on Our Watchlist and 2 We Question
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ... 
Via StockStory
Collegium Pharmaceutical Inc (NASDAQ:COLL) Presents a Compelling Value Investment Case ↗
Via Chartmill
Collegium Pharmaceutical Inc (NASDAQ:COLL) Reports Q4 Revenue Growth but Misses Earnings Estimates ↗
Via Chartmill
COLLEGIUM PHARMACEUTICAL INC (NASDAQ:COLL) Presents a Classic Value Case with High Earnings and Low Valuation ↗
Via Chartmill
News headline image
3 Reasons to Sell COLL and 1 Stock to Buy Instead
Over the last six months, Collegium Pharmaceutical’s shares have sunk to $32.78, producing a disappointing 5.8% loss - a stark contrast to the S&P 500’s 4% g... 
Via StockStory
Topics Stocks Supply Chain
News headline image
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic... 
Via StockStory
News headline image
3 Cash-Producing Stocks Walking a Fine Line
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not... 
Via StockStory
News headline image
1 Value Stock on Our Buy List and 2 Facing Headwinds
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ... 
Via StockStory
Topics ETFs
News headline image
GE HealthCare and Collegium Pharmaceutical Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and pa... 
Via StockStory
Topics Economy Stocks World Trade
News headline image
2 Profitable Stocks to Consider Right Now and 1 We Question
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ... 
Via StockStory
Topics Bonds
News headline image
Collegium's General Counsel Trims His Stake as the Company Doubles Down on ADHD ↗
This specialty pharma firm focused on pain management therapies reported a notable insider sale amid steady revenue and recent stock gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Branded Pharmaceuticals Stocks Q4 Recap: Benchmarking Collegium Pharmaceutical (NASDAQ:COLL)
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Collegium Pharmaceutical (NASDAQ:COLL) an... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Collegium Pharmaceutical EVP Sells Nearly 50,000 Shares Worth $2 Million ↗
Collegium Pharmaceutical, a leader in abuse-deterrent pain therapies, saw its Chief Commercial Officer trim his stake by more than 40%. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
BrightSpring Health Services, Collegium Pharmaceutical, and Phibro Animal Health Shares Are Soaring, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries. ... 
Via StockStory
Topics Economy Stocks
News headline image
3 Healthcare Stocks Walking a Fine Line
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have realiz... 
Via StockStory
News headline image
Why Collegium Pharmaceutical (COLL) Stock Is Trading Lower Today
Shares of pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) fell 6.7% in the afternoon session after the company reported fourth-quarter earnings and revenue that fell short of analysts'... 
Via StockStory
News headline image
Collegium (COLL) Q4 2025 Earnings Call Transcript ↗
Collegium (COLL) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Collegium Pharmaceutical’s (NASDAQ:COLL) Q4 CY2025 Earnings Results: Revenue In Line With Expectations
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 12.9% year on year to $205.4 million. The company’s full-year revenue... 
Via StockStory
News headline image
Collegium Pharmaceutical (COLL) Q4 Earnings: What To Expect
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting results this Thursday before market open. Here’s what to expect. 
Via StockStory
Topics World Trade
News headline image
1 Profitable Stock on Our Watchlist and 2 That Underwhelm
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
News headline image
Collegium Pharmaceutical EVP Sells COLL 17,600 Shares Amid Strong Close of 2025 ↗
An executive vice president at a top pharmaceutical company sold shares towards the end of 2025, while the company's shares reached record numbers that year. 
Via The Motley Fool
Topics Regulatory Compliance
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.